21 results · 21ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

MEDMIRA RAPID H. PYLORI ANTIBODY TEST, MODEL 10714

FDA 510(k)
FDA Class 1 ·Microbiology

Duesseldorf Type Bell Partial

FDA UDI
Heinz Kurz GmbH·EHKM10020231·Ossicular prosthesis, partial

artVeneer life

FDA UDI
Merz Dental GmbH·D7092002023·artVeneer life lower posteriors, L, A3

nGenius

FDA UDI
Stryker Leibinger GmbH & Co. KG·07613327353600·SPINE CLAMP

CosmoLock Pedicle Screw System

FDA UDI
Kalitec Direct LLC·B07311K0120230·Screwdriver, Extended Tab, Fixed Tap Sleeve, As...

DULBECCO'S MODIFIED EAGLE'S MEDIUM, NO. 200-2023

FDA 510(k)
FDA Class 1 ·Hematology

BREAST IMPLANT

FDA Adverse Event
DOW CORNING CORP.·Product code FTR·May 17, 1994

NITRILE PATIENT EXAMINATION GLOVES, POWDER-FREE

FDA 510(k)
FDA Class 1 ·General Hospital

FRIENDLY LIGHT ER:YAG PULSED LASER

FDA 510(k)
FDA Class 2 ·General, Plastic Surgery

DEXTRUS 4136

FDA Adverse Event
Malfunction ·BIOTRONIK SE & CO. KG·Product code NVN·March 13, 2013

PUMP/GRAVITY SOLUTION NO 'Y' SITE

FDA Adverse Event
Malfunction ·BAXTER HEALTHCARE - MALTA·Product code FPA·February 27, 2011

ICY HOT HEAT THERAPY-BACK PATCH

FDA Adverse Event
Injury ·*·Product code IMD·February 20, 2008

ONYX

FDA Adverse Event
Injury ·MICRO THERAPEUTICS, INC. DBA EV3·Product code MFE·October 16, 2024

Verigene Enteric Pathogens Nucleic Acid Test (EP), REF 30-002-023

FDA Recall
Open, Classified ·Luminex Corporation·Product code PCH·June 5, 2023

CLEARSIGN II Amplifier for LABSYSTEM PRO EP Recording System, 120 channels, using firmware version 2.08. The channel numbers in the amplifier are as follows: Material number: H30120020210 - 40 Channel CLEARSIGN II Amplifier, catalog number 2002021; Material number: H30120020220 80 Channel CLEARSIGN II Amplifier, catalog number 2002022; Material number: H30120020230 120 Channel CLEARSIGN II Amplifier, catalog number 2002023; Material number: H30120020240 160 Channel Clearsign II Amplifier, catalog number 2002014. The CLEARSIGN II Amplifier is intended to amplify and condition electrocardiographic signals of biologic origin and pressure transducer input, transmitting this information to a host computer (the LABSYSTEM PRO EP Recording System) that can record and display the information

FDA Enforcement
Class II ·Terminated·Boston Scientific Corporation·June 24, 2015

HAMILTON MEDICAL AG

FDA Adverse Event
Malfunction ·HAMILTON MEDICAL AG·Product code CBK·December 21, 2023

Verigene Enteric Pathogens Nucleic Acid Test (EP), REF 30-002-023

FDA Enforcement
Class II ·Ongoing·Luminex Corporation·July 5, 2023

CLEARSIGN II Amplifier for LABSYSTEM PRO EP Recording System, 120 channels, using firmware version 2.08. The channel numbers in the amplifier are as follows: Material number: H30120020210 - 40 Channel CLEARSIGN II Amplifier, catalog number 2002021; Material number: H30120020220 80 Channel CLEARSIGN II Amplifier, catalog number 2002022; Material number: H30120020230 120 Channel CLEARSIGN II Amplifier, catalog number 2002023; Material number: H30120020240 160 Channel Clearsign II Amplifier, catalog number 2002014. The CLEARSIGN II Amplifier is intended to amplify and condition electrocardiographic signals of biologic origin and pressure transducer input, transmitting this information to a host computer (the LABSYSTEM PRO EP Recording System) that can record and display the information

FDA Recall
Terminated ·Boston Scientific Corporation·Product code DRQ·June 2, 2015

1202 Flex Focus Ultrasound System, cart models UA1214 and UA1814, used with: Flex Focus 200, Flex Focus 300, Flex Focus 400, Flex Focus 500, Flex Focus 700, Flex Focus 800; System, Imaging, Pulsed Doppler, Ultrasonic

FDA Enforcement
Class II ·Ongoing·B-K Medical A/S·November 12, 2025

CADD-Solis Ambulatory Infusion Pumps, Model 2100. Intended for the following uses: Indicated for the following uses: Intra-arterial, subcutaneous, intraperitoneal, in close proximity to nerves, into an intraoperative site, epidural space or subarachnoid space. Therapies that require a continuous rate of infusion, intermittent bolus, and/or with patient-controlled demand doses.

FDA Enforcement
Class I ·Ongoing·Smiths Medical ASD Inc.·August 14, 2024